Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Sebia announces FDA clearance for its Hydrashift 2/4 daratumumab assay

Sebia
Posted on: 26 Jan 18

 
The in vitro diagnostic test, developed in collaboration with Janssen, allows for assessment of response in patients with multiple myeloma by mitigating potential interference induced by daratumumab

Paris, France, January 24, 2018 - Sebia, a world leader in multiple myeloma diagnostics testing and monitoring, announces today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Hydrashift 2/4 daratumumab assay, intended to be used with Hydragel IF, for the qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis. This in vitro diagnostic (IVD) reagent mitigates the daratumumab-mediated interference seen in Immunofixation results for patients with multiple myeloma treated with DARZALEX® (daratumumab), a fully human monoclonal antibody that binds to CD38.

The Hydrashift 2/4 daratumumab Immunofixation assay is the result of a collaboration between Sebia (Paris, France) and Janssen Biotech, Inc. (Horsham, PA, USA), to provide the clinical community with better tools to monitor patients with multiple myeloma in line with the International Myeloma Working Group’s (IMWG) latest recommendations. Sebia received development rights from Janssen and is the worldwide supplier of this assay. Sebia’s broad market coverage will enable patients receiving DARZALEX® in many countries throughout the world to have access to testing. The assay received the CE Mark in November 2016.   

“Sebia is excited to have developed such a novel and innovative IVD assay,” said Jean-Marc Chermette, Sebia’s CEO. “Immunofixation is one of the tests referenced in the IMWG guidelines to assess complete response in a patient with multiple myeloma. This development confirms the company’s commitment and strategic objective to remain the market leader in providing the most advanced diagnostic tools supporting multiple myeloma disease management.”

The Hydrashift 2/4 daratumumab assay is performed on the Sebia Hydrasys 2 agarose gel platform. Sebia has a large established customer base utilizing this platform in academic centers, hospitals and reference laboratories across the world. The implementation of this assay will be easy and seamless in many of these institutions.

About Multiple Myeloma
Myeloma is the second most common blood cancer in the world. Globally, close to 230,000 people live with the disease. More than 110,000 new cases are diagnosed each year.
www.myeloma.org/what-is-multiple-myeloma
 
About Sebia
Sebia a global specialty diagnostic company, develops, manufactures and commercializes IVD tests and analyzers dedicated to the in vitro diagnosis of cancer, inflammatory diseases, diabetes and hemoglobin disorders. Sebia’s focus on electrophoresis techniques enables it to maintain a sustained R&D program, providing access to genuine innovations in any lab. Both agarose gel and capillary assays, and their dedicated automation, are designed to be integrated into the same routine workflow; for gel (Assist, Hydrasys 2 Scan) and for capillary electrophoresis (Capillarys 3 TERA, stand alone or in work cell configuration up to three instruments with tube loader, Capillarys 2 Flex-Piercing, Minicap-Flex Piercing).
www.sebia.com
 

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 26/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.